Physician profile
David W Lam
NPI 1295930972
$2,870.05
in general payments reported to CMS, 2019-2025
37 companies · $503 in 2025
The $503 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.98 · 2020: $29.67 · 2021: $283 · 2022: $462 · 2023: $838 · 2024: $719 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329 · Education: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.87 |
| Education | $731.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $850.47 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $570.32 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $207.92 | 2021-2023 | Myrisk |
| Abbott Laboratories | $169.89 | 2023-2024 | Proclaim |
| Lilly USA, LLC | $100.39 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $87.09 | 2021-2024 | Enhertu |
| Seagen INC. | $83.30 | 2020-2023 | Adcetris, Tukysa |
| Merck Sharp & Dohme LLC | $75.90 | 2020-2025 | Keytruda, Welireg |
| Gilead Sciences, INC. | $63.19 | 2021-2024 | |
| Karyopharm Therapeutics INC. | $59.65 | 2022-2023 | Xpovio |
| Tempus Ai, INC | $58.65 | 2024-2025 | Xt Cdx |
| Tersera Therapeutics LLC | $45.24 | 2023 | Zoladex |
| Adc Therapeutics America, INC. | $35.56 | 2023 | |
| Celgene Corporation | $33.61 | 2022-2025 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $30.67 | 2021-2025 | Opdivo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $27.30 | 2023 | Libtayo |
| Array Biopharma INC | $25.05 | 2022 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Astellas Pharma US INC | $23.45 | 2023 | Padcev |
| Aveo Pharmaceuticals, INC. | $22.78 | 2022 | |
| Mirati Therapeutics, INC. | $21.96 | 2023 | Krazati |
| Sobi, INC | $21.55 | 2024 | |
| Rigel Pharmaceuticals, INC. | $21.29 | 2023 | Rezlidhia, Tavalisse |
| Puma Biotechnology, INC. | $20.94 | 2021 | |
| Clovis Oncology, INC. | $20.36 | 2019 | |
| Progenics Pharmaceuticals, INC. | $20.01 | 2025 | |
| Janssen Biotech, INC. | $19.96 | 2025 | Rybrevant |
| Eisai INC. | $19.07 | 2023 | |
| Coherus Oncology, INC. | $18.50 | 2021 | |
| Daiichi Sankyo INC. | $17.80 | 2025 | Enhertu |
| Ipsen Biopharmaceuticals, INC | $16.23 | 2024 | Onivyde, Tazverik |
| Glaxosmithkline, LLC. | $15.11 | 2023 | Jemperli, Zejula |
| Incyte Corporation | $14.62 | 2019 | |
| Abbvie INC. | $14.36 | 2024 | |
| Acrotech Biopharma INC. | $13.93 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.